Non-alcoholic fatty liver disease: Definition and subtypes

키워드

참고문헌 (91)

1. The Lancet Gastroenterology Hepatology, "Redefining non-alcoholic fatty liver disease : what’s in a name?", Lancet Gastroenterol Hepatol, 5, pp.419~ (2020)
2. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
3. Sberna AL, "European Association for the Study of the Liver(EASL), European Association for the Study of Diabetes(EASD)and European Association for the Study of Obesity(EASO)clinical practice recommendations for the management of nonalcoholic fatty liver disease : evaluation of their application in people with Type 2 diabetes", Diabet Med, 35, pp.368~375 (2018)
4. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
5. Chang Y, "Metabolically healthy obesity and the development of nonalcoholic fatty liver disease", Am J Gastroenterol, 111, pp.1133~1140 (2016)
6. Jung HS, "Smoking and the risk of non-alcoholic fatty liver disease : a cohort study", Am J Gastroenterol, 114, pp.453~463 (2019)
7. Kim TJ, "A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease", J Gastroenterol, 52, pp.1201~1210 (2017)
8. Kim G, "Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease : a 7-year longitudinal study", Hepatology, 68, pp.1755~1768 (2018)
9. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
10. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
11. Chang Y, "Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population", Am J Gastroenterol, 108, pp.1861~1868 (2013)
12. Lee SB, "Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis : an observational cohort study", J Hepatol, 68, pp.1018~1024 (2018)
13. Jang HR, "Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease : a cohort study", Sci Rep, 8, pp.4718~ (2018)
14. Lee JY, "Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea : a review of 589 consecutive liver biopsies in a single center", J Hepatol, 47, pp.239~244 (2007)
15. 정은행, "Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea", Clinical and Molecular Hepatology, 19(3), pp.266~272 (2013), 대한간학회[DOI]
16. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
17. Brunt EM, "Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
18. Brunt EM, "Histopathology of non-alcoholic fatty liver disease", Clin Liver Dis, 13, pp.533~544 (2009)
19. Yeh MM, "Pathology of nonalcoholic fatty liver disease", Am J Clin Pathol, 128, pp.837~847 (2007)
20. Bondini S, "Pathologic assessment of non-alcoholic fatty liver disease", Clin Liver Dis, 11, pp.17~23 (2007)
21. Tandra S, "Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease", J Hepatol, 55, pp.654~659 (2011)
22. Kenichi Ikejima, "Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights", Clinical and Molecular Hepatology, 26(4), pp.728~735 (2020), 대한간학회
23. Teli MR, "The natural history of nonalcoholic fatty liver : a follow-up study", Hepatology, 22, pp.1714~1719 (1995)
24. Ekstedt M, "Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
25. Mazzolini G, "Significance of simple steatosis : an update on the clinical and molecular evidence", Cells, 9, pp.2458~ (2020)
26. Pais R, "A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver", J Hepatol, 59, pp.550~556 (2013)
27. Chalasani N, "Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease", J Hepatol, 48, pp.829~834 (2008)
28. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
29. European Association for the Study of the Liver(EASL), "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
30. Schuppan D, "Determinants of fibrosis progression and regression in NASH", J Hepatol, 68, pp.238~250 (2018)
31. Ludwig J, "Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease", Mayo Clin Proc, 55, pp.434~438 (1980)
32. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
33. Younossi ZM, "Non-alcoholic fatty liver disease-A global public health perspective", J Hepatol, 70, pp.531~544 (2019)
34. Zhai M, "The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017", Sci Rep, 11, pp.5195~ (2021)
35. Brunt EM, "Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
36. Takahashi Y, "Histopathology of nonalcoholic fatty liver disease", nonalcoholic steatohepatitis, 2014, pp.20, 15539~15548
37. Argo CK, "Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis", J Hepatol, 51, pp.371~379 (2009)
38. Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
39. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
40. Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)
41. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
42. Gwyneth Soon, "Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective", Clinical and Molecular Hepatology, 27(1), pp.44~57 (2021), 대한간학회[DOI]
43. Tiniakos DG, "Nonalcoholic fatty liver disease", nonalcoholic steatohepatitis : histological diagnostic criteria and scoring systems, 2010, pp.22, 643~650
44. Caldwell SH, "NASH and cryptogenic cirrhosis : a histological analysis", Ann Hepatol, 8, pp.346~352 (2009)
45. Caldwell SH, "Cryptogenic cirrhosis : clinical characterization and risk factors for underlying disease", Hepatology, 29, pp.664~669 (1999)
46. Poonawala A, "Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis : a case-control study", Hepatology, 32(4 Pt 1), pp.689~692 (2000)
47. Kabbany MN, "Prevalence of nonalcoholic steatohepatitisassociated cirrhosis in the United States : an analysis of national health and nutrition examination survey data", Am J Gastroenterol, 112, pp.581~587 (2017)
48. Loomba R, "The 20% rule of NASH progression : the natural history of advanced fibrosis and cirrhosis caused by NASH", Hepatology, 70, pp.1885~1888 (2019)
49. Dam-Larsen S, "Long term prognosis of fatty liver : risk of chronic liver disease and death", Gut, 53, pp.750~755 (2004)
50. Brunt EM, "Histopathology of nonalcoholic fatty liver disease", World J Gastroenterol, 16, pp.5286~5296 (2010)
51. Bugianesi E, "Expanding the natural history of nonalcoholic steatohepatitis : from cryptogenic cirrhosis to hepatocellular carcinoma", Gastroenterology, 123, pp.134~140 (2002)
52. Nair S, "Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?", Hepatology, 36, pp.150~155 (2002)
53. Marrero JA, "Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma", J Hepatol, 42, pp.218~224 (2005)
54. Pais R, "Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants", Clin Gastroenterol Hepatol, 13, pp.992~999 (2015)
55. Younossi Z, "The conundrum of cryptogenic cirrhosis : adverse outcomes without treatment options", J Hepatol, 69, pp.1365~1370 (2018)
56. Bhala N, "The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study", Hepatology, 54, pp.1208~1216 (2011)
57. Thuluvath PJ, "Is cryptogenic cirrhosis different from NASH cirrhosis?", J Hepatol, 68, pp.519~525 (2018)
58. Ito T, "The epidemiology of NAFLD and lean NAFLD in Japan : a metaanalysis with individual and forecasting analysis, 1995-2040", Hepatol Int, 15, pp.366~379 (2021)
59. Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
60. Young S, "Prevalence and profile of nonalcoholic fatty liver disease in lean adults : systematic review and meta-analysis", Hepatol Commun, 4, pp.953~972 (2020)
61. Wang W, "Lean nonalcoholic fatty liver disease(Lean-NAFLD)and the development of metabolic syndrome : a retrospective study", Sci Rep, 12, pp.10977~ (2022)
62. Leung JC, "Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients", Hepatology, 65, pp.54~64 (2017)
63. Chrysavgis L, "Nonalcoholic fatty liver disease in lean subjects : prognosis, outcomes and management", World J Gastroenterol, 26, pp.6514~6528 (2020)
64. Dimitrios Patoulias, "Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?", Clinical and Molecular Hepatology, 26(4), pp.582~583 (2020), 대한간학회[DOI]
65. Zou B, "Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016", J Intern Med, 288, pp.139~151 (2020)
66. Hagström H, "Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease : A long-term followup study", Hepatol Commun, 2, pp.48~57 (2017)
67. Lei L, "Association between non-alcoholic fatty liver disease and metabolically healthy deterioration across different body shape phenotypes at baseline and change patterns", Sci Rep, 12, pp.14786~ (2022)
68. Kim Y, "Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease", Liver Int, 39, pp.1884~1894 (2019)
69. Boulouta A, "The impact of metabolic health on nonalcoholic fatty liver disease(NAFLD). A single center experience", Clin Res Hepatol Gastroenterol, 46, pp.101896~ (2022)
70. Rey-López JP, "The prevalence of metabolically healthy obesity : a systematic review and critical evaluation of the definitions used", Obes Rev, 15, pp.781~790 (2014)
71. Eslam M, "MAFLD : a consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
72. Liu J, "Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults", Clin Gastroenterol Hepatol, 20, pp.e573~e582 (2022)
73. Cheng Han Ng, "Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name", Clinical and Molecular Hepatology, 28(4), pp.790~801 (2022), 대한간학회
74. Kim M, "Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea", Liver Int, 42, pp.1536~1544 (2022)
75. Lin S, "Comparison of MAFLD and NAFLD diagnostic criteria in real world", Liver Int, 40, pp.2082~2089 (2020)
76. Yamamura S, "MAFLD identifies patients with significant hepatic fibrosis better than NAFLD", Liver Int, 40, pp.3018~3030 (2020)
77. Seong Hee Kang, "From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?", Clinical and Molecular Hepatology, 27(2), pp.257~269 (2021), 대한간학회[DOI]
78. Silvia Sookoian, "Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology", Clinical and Molecular Hepatology, 26(4), pp.461~475 (2020), 대한간학회[DOI]
79. Liu YL, "Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma", J Hepatol, 61, pp.75~81 (2014)
80. Krawczyk M, "HCC and liver disease risks in homozygous PNPLA3 p. I148M carriers approach monogenic inheritance", J Hepatol, 62, pp.980~981 (2015)
81. Younossi ZM, "Nonalcoholic fatty liver disease in lean individuals in the United States", Medicine(Baltimore), 91, pp.319~327 (2012)
82. Yu J, "The pathogenesis of nonalcoholic fatty liver disease : interplay between diet, gut microbiota, and genetic background", Gastroenterol Res Pract, 2016, pp.2862173~ (2016)
83. Speliotes EK, "PNPLA3variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease", Hepatology, 52, pp.904~912 (2010)
84. Valenti L, "Homozygosity for the patatin-like phospholipase-3", adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, 2010, pp.51, 1209~1217
85. Musso G, "TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD", J Hepatol, 64, pp.979~981 (2016)
86. Basyte-Bacevice V, "TM6SF2 and MBOAT7 Gene variants in liver fibrosis and cirrhosis", Int J Mol Sci, 20, pp.1277~ (2019)
87. Su W, "Role of HSD17B13 in the liver physiology and pathophysiology", Mol Cell Endocrinol, 489, pp.119~125 (2019)
88. Abul-Husn NS, "A protein-truncating HSD17B13 variant and protection from chronic liver disease", N Engl J Med, 378, pp.1096~1106 (2018)
89. Chalasani N, "Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease", Gastroenterology, 139, pp.1567~1576 (2010)
90. Di Filippo M, "Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia", J Hepatol, 61, pp.891~902 (2014)
91. Petta S, "Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease", Hepatology, 66, pp.1885~1893 (2017)

관련 논문AI추천